Attenuation of nocturnal asthma by cromakalim
| Autor: | A.J. Williams, T.H. Lee, T. Vyse, F. Chiew, G.M. Cochrane, E. Lavender, D.H. Richards, A. Hopkirk, S. Owen, P. Stone, S. Church, A.A. Woodcock |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cromakalim Nocturnal Placebo chemistry.chemical_compound Double-Blind Method Forced Expiratory Volume Medicine Humans Benzopyrans Pyrroles Dosing Morning Asthma Randomized Controlled Trials as Topic Analysis of Variance Dose-Response Relationship Drug business.industry Respiratory disease General Medicine Middle Aged medicine.disease Crossover study Bronchodilator Agents Circadian Rhythm chemistry Anesthesia Female business Half-Life |
| Zdroj: | Lancet (London, England). 336(8711) |
| ISSN: | 0140-6736 |
| Popis: | In a randomised, double-blind, crossover study, single oral doses of cromakalim, a potassium-channel activator, or placebo were given to 23 patients with nocturnal asthma. There was a significant reduction (p less than 0.005) in the early morning fall in forced expiratory volume in 1 s (FEV1) after 0.5 mg cromakalim (fall 9.8% [SEM 3.2%]) compared with placebo (18.5 [2.8]%). In a repeat dosing study, administration of 0.25 mg and 0.5 mg cromakalim on 5 consecutive nights to a further group of 8 asthmatic subjects significantly reduced the early morning fall in FEV1 from 28.7 (6.5)% after placebo to 19 (4.2)% after 0.25 mg and 14.9 (6.5)% after 0.5 mg. Potassium-channel activators may be useful in the treatment of asthma, especially for nocturnal symptoms. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|